November 6, 2025 7:51am

As earnings’ releases remain as the sector focus

Earnings today: Entrada Therapeutics (TRDA), Regenxbio (RGNX), Moderna (MRNA) and Vericel (VCEL)

 

The shutdown enters its 37th day and 6th week, 2nd month, with lawmakers still unable to agree on a funding bill … as Democrats block the 16th voting negotiation

Pre-open Signals: 3 Negative, 2 Positive Indications with a lot of drops

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

The past, present and future values of RMi’s analysis sheds light on the cell and gene therapy’s (C&GT) sector’s “current” acrobatics

Wednesday night’s … RMi Closing Bell: Barely … https://www.regmedinvestors.com/articles/14183

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

 

Thursday: The pre-open Dow futures are UP +0.04% or (+20 points), the S&P futures are UP +0.16% or (+11 points) and the Nasdaq futures are UP +0.15% or (+37 points)

  • Stock futures were positive and barely moving, Thursday, 11/6
  • European markets were falling,
  • Asia Pacific markets were positive

Data drivers:

  • Outplacement firm Challenger, Gray & Christmas says job cuts for October totaled 153,074, a 183% surge from September and 175% higher than the same month a year ago. It was the highest level for any October since 2003. Companies in the technology sector announced 33,281 cuts, nearly six times the level in September.
  • Consumer products also saw a sharp gain to 3,409, while nonprofits, an area hit hard by the shutdown, listed 27,651 cuts year to date, up 419% from the same point in 2024.
  • In total, companies have announced 1.1 million cuts this year, a 65% increase from a year ago and the highest level since the Covid pandemic year of 2020. October saw the highest total for any month in the fourth quarter since 2008.

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Wednesday: The Dow closed UP +225.86 points or +0.48%, the S&P closed UP +24.74 points or +0.37% while the Nasdaq closed UP +151.16 points or +0.65%
  • Tuesday: The Dow closed DOWN -251.07 points or -0.53%, the S&P closed DOWN -80.30 points or -1.17% while the Nasdaq closed DOWN -486.087 points or -2.04%
  • Monday: The Dow closed DOWN -226.19 points or -0.48%, the S&P closed UP +11.77 points or +0.17% while the Nasdaq closed UP +109,766 points or +0.46%
  • Last week: The S&P 500 was up 1.5%, the Dow +0.9% and the Nasdaq is up +3.2%
  • The previous week: the S&P 500 was up +2%, the Dow +2% and the Nasdaq added +2%.
  • Last month: the S&P 500 was up +2.3%, the Nasdaq’s +4.7% and the Dow’s is up +2.5%.
  • 2025 to date: the S&P is up +16%, the Nasdaq +22% and thew Dow +12%

Q4 – November, 1 positive and 2 negative closes

  • October, 1 neutral, 10 positive and 12 negative closes
  • Q3 – September, 1 holiday, 9 negative and 12 positive closes; August - 11 negative and 9 positive closes; July – 1 market holiday, 13 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Info:

Sarepta Therapeutics (SRPT) closed up +$2.47 after Tuesday’s -$8.25 and Monday’s +$0.44 with a negative -$0.19 or -1.36% pre-open

Intellia Therapeutics (NTLA) closed up +$1.37 with a negative -$0.38 or -2.80% pre-open

Supernus Therapeutics (SUPN) closed down -$9.89 after Tuesday’s +$1.30 and Monday’s +$0.57 with a negative -$0.47 or -1% pre-open

Lenz Therapeutics (LENZ -$6.58 after Tuesday’s +$0.12 and Monday’s -$1.79 with a positive +$0.98 or +4.56% pre-open

BioNTech (BNTX -$1.40 after Tuesday’s +$0.88 and Monday’s +$0.04 with a positive +$0.31 or +0.30% pre-open

 

The BOTTOM LINE: Still feeling the drag…

The 3rd trading day of November began on a positive note flipped back and forth to close barely positive

  • As the government shutdown continues becoming the longest in American history.

I got on my computer/laptop/ my horse with a lantern as I ride yelling … “earnings are here, earnings are here”!

  • Q3 Earnings this week: followed by Cellectis SA CLLS) on 11/7 with uniQure NV (QURE) and Capricor Therapeutics (CAPR) on 11/10

Expect earnings’ results that meet, beat or miss revenue estimates, EPS as to pricing expectations, consensus … sector earnings while LPS (loss-per-share) assumes adjustments

  • As sector earnings meet, beat or miss expectations; whipsaw actions could ensue depreciations or the stock market heads south, back pedal -- fast.

Welcome to my world of defining the “grey’ in our universe!

  • “I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

November to understand the flow review some of October:

New week and month, November:

  • 11/5 - Wednesday closed positive with 20 positive, 18 negative and 2 flats
  • 11/4 – Tuesday closed negative with 10 positive, 30 negative and 0 flat
  • 11/3 – Monday closed negative with 10 positive, 26 negative and 4 flats

Last week:

  • 10/31 – Friday closed positive with 28 positive, 11 negative and 1 flat
  • 10/30 – Thursday closed negative with 13 positive, 25 negative and 2 flats
  • 10/29 - Wednesday closed negative with 9 positive, 30 negative and 1 flat
  • 10/28 -Tuesday closed negative with 16 positive, 21 negative and 3 flats
  • 10/27- Monday closed negative with 18 positive, 22 negative and 0 flats

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.